John Overdeck Two Sigma Investments
John Overdeck is a co-founder of Two Sigma Investments, one of the world’s leading quantitative and technology-driven investment firms. Two Sigma applies data science, machine learning, and large-scale computing to markets across asset classes. Overdeck’s firm is a central reference point in discussions of modern systematic investing.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$244M |
| 2 |
Pfizer
PFE
|
+$234M |
| 3 |
Nike
NKE
|
+$201M |
| 4 |
Tesla
TSLA
|
+$200M |
| 5 |
S&P Global
SPGI
|
+$196M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$305M |
| 2 |
Advanced Micro Devices
AMD
|
+$241M |
| 3 |
Invesco QQQ Trust
QQQ
|
+$231M |
| 4 |
Merck
MRK
|
+$199M |
| 5 |
State Street Technology Select Sector SPDR ETF
XLK
|
+$190M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 15.1% |
| 2 | Healthcare | 11.63% |
| 3 | Consumer Discretionary | 11.09% |
| 4 | Financials | 10.76% |
| 5 | Industrials | 9.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2001
iShares Morningstar Growth ETF
ILCG
$3.17B
| $868K | ﹤0.01% |
11,500
-15,800
| -58% | -$1.14M |
|
2002
Merchants Bancorp
MBIN
$2.46B
| $864K | ﹤0.01% |
20,003
-5,712
| -22% | -$239K |
|
2003
T. Rowe Price Blue Chip Growth ETF
TCHP
$2.16B
| $861K | ﹤0.01% |
24,400
+6,700
| +38% | +$224K |
|
|
HTB
2004
HomeTrust Bancshares
HTB
$773M
| $861K | ﹤0.01% |
31,478
-2,812
| -8% | -$73.9K |
|
|
SFBS
2005
ServisFirst Bancshares
SFBS
$4.74B
| $860K | ﹤0.01% |
25,932
+132
| +0.5% | +$4.2K |
|
|
BLD
2006
DELISTED
TopBuild
BLD
| $859K | ﹤0.01% |
1,950
-6,083
| -76% | -$2.38M |
|
2007
Coursera
COUR
$1.6B
| $859K | ﹤0.01% |
61,286
-51,196
| -46% | -$869K |
|
2008
First Financial Corp
THFF
$943M
| $859K | ﹤0.01% |
22,400
+4,519
| +25% | +$175K |
|
|
EGRX
2009
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $856K | ﹤0.01% |
163,435
-44,179
| -21% | -$242K |
|
2010
Cenovus Energy
CVE
$58.6B
| $855K | ﹤0.01% |
+42,762
| New | +$730K |
|
2011
United Natural Foods
UNFI
$2.88B
| $854K | ﹤0.01% |
74,320
-303,337
| -80% | -$4.41M |
|
2012
CNB Financial Corp
CCNE
$1B
| $852K | ﹤0.01% |
41,784
+8,749
| +26% | +$182K |
|
|
CFB
2013
DELISTED
CrossFirst Bankshares, Inc. Common Stock
CFB
| $850K | ﹤0.01% |
61,435
-13,133
| -18% | -$176K |
|
2014
Pulmonx
LUNG
$108M
| $846K | ﹤0.01% |
91,235
-77,705
| -46% | -$911K |
|
2015
Financial Institutions
FISI
$802M
| $846K | ﹤0.01% |
44,936
-5,003
| -10% | -$99K |
|
2016
Orion
OEC
$346M
| $845K | ﹤0.01% |
35,933
-107,570
| -75% | -$2.49M |
|
2017
Tenaris
TS
$27.2B
| $844K | ﹤0.01% |
21,494
| – | – |
|
2018
Rogers Corp
ROG
$2.26B
| $844K | ﹤0.01% |
7,110
-8,418
| -54% | -$985K |
|
2019
Agilysys
AGYS
$3.21B
| $843K | ﹤0.01% |
10,001
-33,592
| -77% | -$2.72M |
|
2020
1stdibs.com
DIBS
$152M
| $842K | ﹤0.01% |
141,330
+22,823
| +19% | +$116K |
|
2021
Alphatec Holdings
ATEC
$1.44B
| $840K | ﹤0.01% |
60,946
-49,554
| -45% | -$735K |
|
|
SEMR
2022
DELISTED
Semrush
SEMR
| $836K | ﹤0.01% |
63,077
-26,361
| -29% | -$317K |
|
2023
Goodyear
GT
$1.81B
| $836K | ﹤0.01% |
60,905
-89,895
| -60% | -$1.18M |
|
2024
Frontdoor
FTDR
$5.77B
| $833K | ﹤0.01% |
25,575
-144,952
| -85% | -$4.7M |
|
|
CERE
2025
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $833K | ﹤0.01% |
19,700
| – | – |
|
Similar funds
John Overdeck's Q1 2024 Portfolio in Review
As of Q1 2024, John Overdeck held 3,518 positions worth $42.6B, down 2.1% from $43.5B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
John Overdeck withdrew a net $4.42B in Q1 2024, closing 532 positions and reducing 1,392 holdings. Its most notable exit was Rivian, an estimated $158M position sold in full.
By sector, the portfolio is most concentrated in Technology at 15% of assets, down from 18% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, John Overdeck opened a new position in Pfizer worth $234M.
- John Overdeck's largest Q1 2024 buy was Pfizer: 8,419,014 shares worth $234M.
- John Overdeck added most to Gilead Sciences in Q1 2024, an estimated $244M increase.
- John Overdeck's biggest Q1 2024 reduction was NVIDIA, cutting an estimated $305M.
- John Overdeck fully exited Rivian in Q1 2024, selling an estimated $158M.
- John Overdeck's ten largest holdings make up 9% of its $42.6B portfolio in Q1 2024.
- John Overdeck opened 408 new positions and closed 532 in Q1 2024.
- John Overdeck's portfolio value fell 2.1% quarter-over-quarter to $42.6B.
Based on Two Sigma Investments's 13F filing for Q1 2024, filed 15 May 2024.